NASDAQ:APLS - Nasdaq - US03753U1060 - Common Stock - Currency: USD
Overall APLS gets a fundamental rating of 3 out of 10. We evaluated APLS against 558 industry peers in the Biotechnology industry. APLS has a bad profitability rating. Also its financial health evaluation is rather negative. APLS is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -27.71% | ||
ROE | -136.21% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 83% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 2.76 | ||
Debt/FCF | N/A | ||
Altman-Z | -2.42 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 4.08 | ||
Quick Ratio | 3.62 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
16.93
-0.48 (-2.76%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 2.74 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 12.96 | ||
P/tB | 12.96 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -27.71% | ||
ROE | -136.21% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 83% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 2.76 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 6.56% | ||
Cap/Sales | 0.02% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 4.08 | ||
Quick Ratio | 3.62 | ||
Altman-Z | -2.42 |